Wellcome Trust launches study of 10,000 human genomes in UK
On the 10th anniversary of the completion of the first draft of the human genome – a draft which had taken 10 years to complete – the Wellcome Trust today launches a project to decode the genomes of 10,000 people over the next three years. This will be one of the largest genome sequencing programmes ever undertaken and will analyse the genomes of the equivalent of one in 6000 people in the UK.
The UK10K project is expected to uncover many rare genetic variants that are important in human disease, giving a much deeper picture of genetics that can be applied to other studies both in the UK and around the world. It is being funded through a £10.5 million strategic award to the Wellcome Trust Sanger Institute in collaboration with clinical researchers from around the UK, using samples and cohort data collected over many years.
There are two components to the UK10K project:
- the genomes of 4,000 people, who have each been studied for many diseases and traits over many years, will be completely sequenced
- the gene-containing regions of the genomes of 6,000 people with extreme obesity, neurodevelopmental disease and other conditions will also be studied.
“Although genetics over the past five years has yielded a rich harvest of hundreds of variants associated with disease, much more remains to be discovered. With this award, we are seizing the chance to use technological advances in DNA sequencing to find variants that have even greater consequence for health.”
Dr Richard Durbin Principal Investigator on the Project, from the Wellcome Trust Sanger Institute
The 4,000 genomes will be from two important groups of people who have been studied for many years – the TwinsUK and ALSPAC (Avon Longitudinal Study of Parents and Children – also known as Children of the 90s) studies. The first includes 11,000 twins born in the UK, some of whom have taken part in studies for more than 18 years. ALSPAC includes more than 9,000 people originally from Avon in southwest UK, followed from birth in 1991/2. The data for each group includes extensive description of their health and their development.
Studying this large group will help researchers build a near-complete catalogue of genetic variation in these 4,000 people. The depth of information recorded from them will provide a real opportunity to tie genetic variants to individual differences in health-related measurements. This should help identify the few thousand genetic variants – amongst the 3 million each of us carries – that are important in disease.
The information gathered from these 4,000 will be strengthened by the second component of 6,000 people, recruited by clinicians, who have a severe effect thought to have a genetic cause. These people have one of several conditions, including severe obesity, autism, schizophrenia and congenital heart disease. The gene-containing regions of their genomes – known as ‘exomes’ – which are likely to include the genetic variants important in their condition, will be analysed using new methods based in part on cutting-edge techniques developed at the Wellcome Trust Sanger Institute.
“We are fortunate in the UK to have such excellent collections of clinical samples provided by volunteers to help research and to help others. 10,000 volunteers have contributed to this, the largest genome sequencing project so far undertaken. It’s a stunning commentary on the generosity of participants in UK studies.”
Professor Tim Spector who leads the TwinsUK study at King’s College London
The researchers point out that the results will have most immediate impact in genetics, contributing to an ongoing transformation of our understanding of human genetic variation. In some cases this may have direct clinical relevance. But more often it will lead to advances in our understanding of disease biology, which should, in time, reach through to medical applications.
UK10K starts exactly 10 years after the draft of the first human reference genome was announced by the Human Genome Project.
“The pace of technological change is extraordinary. We can now study the genome sequences of 10,000 people in three years. Just a decade ago it took much more time and money to decode just a single sequence. The involvement of clinicians, researchers and, most importantly, the thousands of people who have donated DNA samples, will help us to correlate genetic variation with individual variation in health and disease, and help to deliver on the long term promise of the human genome project.”
Sir Mark Walport Director of the Wellcome Trust
The UK10K project was co-developed by Professor Leena Peltonen, former head of Human Genetics at the Wellcome Trust Sanger Institute. Professor Peltonen passed away on 11 March 2010 at her home in Finland after a long battle with cancer.
“This project was co-developed by the amazingly energetic and inspiring Professor Leena Peltonen, who sadly died three months ago. I know Leena saw this project as a major opportunity to translate genomics to medical relevance, and we are excited about the opportunity to deliver a project of which she would be proud.”
Dr Richard Durbin Sanger Institute
More information
Selected websites
The Wellcome Trust Sanger Institute
The Wellcome Trust Sanger Institute, which receives the majority of its funding from the Wellcome Trust, was founded in 1992. The Institute is responsible for the completion of the sequence of approximately one-third of the human genome as well as genomes of model organisms and more than 90 pathogen genomes. In October 2006, new funding was awarded by the Wellcome Trust to exploit the wealth of genome data now available to answer important questions about health and disease.
The Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests.
